JUNE 22, 2026
Trump Administration Launches "Operation Trial Blazer" to Expand Domestic Early-Stage Clinical Trials
The Trump administration announced "Operation Trial Blazer," a joint effort between the National Institutes of Health and the Food and Drug Administration aimed at streamlining early-stage pharmaceutical clinical trials in the United States. HHS Secretary Robert F. Kennedy Jr. described the initiative as intended to "restore America's leadership in clinical research, remove unnecessary barriers, and bring more clinical research and investment back to the United States." Acting FDA Commissioner Kyle Diamantas said the agency is developing a pilot program for Phase 1 clinical trials that could reduce timelines by 6 to 12 months.
The Trump administration unveiled Operation Trial Blazer, framing the initiative as a response to the migration of pharmaceutical research abroad and a slowdown in domestic drug approvals that officials said has frustrated drugmakers over the past year.
Acting FDA Commissioner Kyle Diamantas told reporters the agency is building a pilot program for Phase 1 clinical trials and working to clarify expectations for trial sponsors, with the goal of cutting approval timelines by 6 to 12 months. Diamantas said the FDA would continue collaborating with academia, government, and the private sector to ensure "a regulatory framework is responsive to the realities of modern science."
NIH Director Jay Bhattacharya described his agency's central objective as developing reusable clinical trial networks — infrastructure that, once built, could be deployed across multiple trials rather than rebuilt for each one. Various NIH branches, including the National Center for Advancing Translational Science and the National Cancer Institute, are also working to integrate artificial intelligence and cell-based models into early-stage research, according to the Washington Examiner.